A PHASE-II STUDY OF THIOTEPA IN CHILDREN WITH RECURRENT SOLID TUMOR MALIGNANCIES - A CHILDRENS CANCER GROUP-STUDY

Authors
GEYER JR BALIS FM KRAILO MD HEIDEMAN R BROXSON E SATO JK POPLACK D BLEYER WA
Citation
Jr. Geyer et al., A PHASE-II STUDY OF THIOTEPA IN CHILDREN WITH RECURRENT SOLID TUMOR MALIGNANCIES - A CHILDRENS CANCER GROUP-STUDY, Investigational new drugs, 13(4), 1995, pp. 337-342
Citations number
11
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
13
Issue
4
Year of publication
1995
Pages
337 - 342
Database
ISI
SICI code
0167-6997(1995)13:4<337:APSOTI>2.0.ZU;2-W
Abstract
A Phase II study of thioTEPA was performed by the Children's Cancer Gr oup. ThioTEPA was administered intravenously every three weeks, at a d ose of 65 mg/m(2). Pediatric patients with recurrent sarcomas were tar geted, but patients with other tumor diagnoses were also eligible. Tox icity was primarily hematopoietic, with thrombocytopenia being predomi nant. ThioTEPA did not demonstrate significant activity in the target tumor groups evaluated.